Treeline Biosciences Raises $200 Million Series A Extension as Phase 1 Trials Begin for Three Oncology Programs
Treeline Biosciences, a Massachusetts-based oncology-focused biotechnology company, has announced the initiation of Phase 1 clinical trials for three of its drug candidates and the closing of a $200 million Series A extension, bringing its total funding to $1.1 billion. The trials involve TLN-121, a BCL6 degrader; TLN-372, a pan-KRAS inhibitor; and TLN-254, an EZH2 inhibitor. These programs are being studied in patients with lymphoma and cancers harboring specific KRAS mutations.
Founded in 2021 by Dr. Josh Bilenker and Dr. Jeff Engelman, both experienced oncologists, Treeline aims to develop precision medicines targeting challenging cancer drivers. The company’s approach integrates computational tools with in-house research to identify and advance therapeutic candidates. The recent funding round was led by AI Life Sciences, an affiliate of Access Industries, and included participation from ARCH Venture Partners, OrbiMed, GV, KKR, accounts advised by T. Rowe Price Associates, Inc., Ajax Health/Zeus, Casdin Capital, Fidelity Management & Research Company, Aisling Capital, Rock Springs Capital, and Exor.
The initiation of these Phase 1 trials marks a significant milestone for Treeline, demonstrating progress in its oncology pipeline. The company plans to submit an investigational new drug (IND) application for a fourth program early next year and expects to enter IND-enabling studies for three other internal programs following the Phase 1 readouts. This strategic approach reflects Treeline’s commitment to building a sustainable and innovative biopharmaceutical company.
With the additional funding and advancing clinical programs, Treeline Biosciences is poised to make significant contributions to the field of oncology, aiming to provide new treatment options for patients with challenging cancers.
